microRNA-200a/b/c/-429家族在卵巢癌中的研究进展

陈虹; 匡洪影; 周颖; 林文华; 林超; 陈琼华

doi:10.16766/j.cnki.issn.1674-4152.004222

microRNA-200a/b/c/-429家族在卵巢癌中的研究进展

doi: 10.16766/j.cnki.issn.1674-4152.004222

陈虹¹,
匡洪影²,
周颖¹,
林文华¹,
林超¹,
陈琼华^1, ,

1.
厦门大学附属第一医院妇产科，福建厦门 361003
2.
黑龙江中医药大学附属第一医院妇产科，黑龙江哈尔滨 150040

基金项目:

福建省自然科学基金项目 2022J05310

详细信息

通讯作者:
陈琼华，E-mail: docchenqionghua@163.com

中图分类号: R737.31 R730.2
计量
- 文章访问数: 1
- HTML全文浏览量: 1
- PDF下载量: 0
- 被引次数: 0
出版历程
- 收稿日期: 2024-04-07

Research progress of microRNA-200a/b/c/-429 family in ovarian cancer

1.
Department of Obstetrics and Gynecology, the First Affiliated Hospital of Xiamen University, Xiamen, Fujian 361003, China

摘要

摘要: 本文系统性探讨miR-200家族在肿瘤中的作用机制，特别聚焦于miR-200a/b/c/-429家族的功能及其在肿瘤发生与发展中的重要作用。作为一组关键的调控分子，miR-200家族在肿瘤生物学领域中具有重要地位。这些家族成员通过调节肿瘤细胞的生物学行为，有效影响肿瘤细胞的增殖、转移、侵袭以及化疗耐药等过程，进而参与肿瘤发生和进展等多个环节，特别是miR-200家族在上皮细胞向间质细胞转化中发挥重要作用，此外，该家族还通过调节细胞增殖与凋亡通路，进一步影响肿瘤细胞的生存与死亡，从而促进肿瘤细胞的扩散。miR-200家族不仅在肿瘤细胞侵袭和转移中发挥着重要作用，还可能作为卵巢癌的潜在诊断和预后判断标志物。未来研究应着重于阐明miR-200家族的具体分子机制和作用网络，探索其在其他肿瘤类型中的功能，并探讨如何将这些发现转化为临床应用，以期为肿瘤的早期诊断和靶向治疗提供新的思路和策略。深入研究miR-200家族在肿瘤中的作用机制，有助于理解肿瘤生物学特性，并促进创新治疗策略的发展，从而提高患者生存率，具有重要的科学与临床价值。
- 卵巢癌 /
- miR-200a/b/c/-429家族 /
- 生物标志物 /
- 化疗耐药 /
- 治疗策略
Abstract: This article explores the functional mechanisms of the miR-200 family in tumorigenesis, specifically focusing on the contributions of miR-200a/b/c/-429 to cancer initiation and progression. The miR-200 family plays a crucial role in tumor biology by influencing growth, spread, invasion, and chemotherapy resistance. They are vital in the epithelial-to-mesenchymal transition, which aids tumor spread, and also regulate tumor cell survival and growth, contributing to cancer dissemination. The miR-200 family plays a key role in tumor cell invasion and metastasis and holds potential as diagnostic and prognostic markers for ovarian cancer. Future research should investigate the mechanisms in various tumors and apply these insights for early diagnosis and treatment strategies. Studying the miR-200 family in tumors can provide insights into their functions, improving treatment options and enhancing survival with significant scientific and clinical benefits.
- Ovarian cancer /
- miR-200a/b/c/-429 family /
- Biomarkers /
- Chemotherapy resistance /
- Treatment strategies
利益冲突 无

HTML全文

参考文献(44)

[1]	HILL M, TRAN N. miRNA interplay: mechanisms and consequences in cancer[J]. Dis Model Mech, 2021, 14(4): dmm047662. DOI: 10.1242/dmm.047662.
[2]	MEHTEROV N. Role of microRNAs in cancer development and treatment[J]. Int J Mol Sci, 2023, 24(13): 11058. DOI: 10.3390/ijms241311058.
[3]	HO P T B, CLARK I M, LE L T T. MicroRNA-based diagnosis and therapy[J]. Int J Mol Sci, 2022, 23(13): 7167. DOI: 10.3390/ijms23137167.
[4]	ANDERSEN G B, TOST J. Circulating miRNAs as biomarker in cancer[J]. Recent Results Cancer Res, 2020, 215: 277-298.
[5]	HUSSEN B M, HIDAYAT H J, SALIHI A, et al. MicroRNA: a signature for cancer progression[J]. Biomed Pharmacother, 2021, 138: 111528. DOI: 10.1016/j.biopha.2021.111528.
[6]	FERRAGUT CARDOSO A P, BANERJEE M, NAIL A N, et al. miRNA dysregulation is an emerging modulator of genomic instability[J]. Semin Cancer Biol, 2021, 76: 120-131. doi: 10.1016/j.semcancer.2021.05.004
[7]	AKBARZADEH M, MIHANFAR A, AKBARZADEH S, et al. Crosstalk between miRNA and PI3K/AKT/mTOR signaling pathway in cancer[J]. Life Sci, 2021, 285: 119984. DOI: 10.1016/j.lfs.2021.119984.
[8]	SAFA A, ABAK A, SHOOREI H, et al. MicroRNAs as regulators of ERK/MAPK pathway: a comprehensive review[J]. Biomed Pharmacother, 2020, 132: 110853. DOI: 10.1016/j.biopha.2020.110853.
[9]	HE B, ZHAO Z, CAI Q, et al. miRNA-based biomarkers, therapies, and resistance in cancer[J]. Int J Biol Sci, 2020, 16(14): 2628-2647. doi: 10.7150/ijbs.47203
[10]	KLICKA K, GRZYWA T M, MIELNICZUK A, et al. The role of miR-200 family in the regulation of hallmarks of cancer[J]. Front Oncol, 2022, 12: 965231. DOI: 10.3389/fonc.2022.965231.
[11]	JO H, SHIM K, JEOUNG D. Potential of the miR-200 Family as a target for developing anti-cancer therapeutics[J]. Int J Mol Sci, 2022, 23(11): 5881. DOI: 10.3390/ijms23115881.
[12]	CAVALLARI I, CICCARESE F, SHAROVA E, et al. The miR-200 family of micrornas: fine tuners of epithelial-mesenchymal transition and circulating cancer biomarkers[J]. Cancers (Basel), 2021, 13(23): 5874. DOI: 10.3390/cancers13235874.
[13]	BUSTOS M A, ONO S, MARZESE D M, et al. MiR-200a regulates CDK4/6 inhibitor effect by targeting CDK6 in metastatic melanoma[J]. J Invest Dermatol, 2017, 137(9): 1955-1964. doi: 10.1016/j.jid.2017.03.039
[14]	HOU X, YANG L, JIANG X, et al. Role of microRNA-141-3p in the progression and metastasis of hepatocellular carcinoma cell[J]. Int J Biol Macromol, 2019, 128: 331-339. doi: 10.1016/j.ijbiomac.2019.01.144
[15]	TAN T, XU X H, LU X H, et al. MiRNA-200a-3p suppresses the proliferation, migration and invasion of non-small cell lung cancer through targeting IRS2[J]. Eur Rev Med Pharmacol Sci, 2020, 24(2): 712-720.
[16]	MU J W, ZHOU X Y, WANG Q J, et al. MicroRNA-141-3p promoted the progression of nasopharyngeal carcinoma through targeting DLC1[J]. Eur Rev Med Pharmacol Sci, 2020, 24(21): 11105-11113.
[17]	李栗扬, 徐鹏, 王蓓蒂, 等. MicroRNA-429在妇科恶性肿瘤中的研究进展[J]. 中华全科医学, 2021, 19(6): 1013-1016, 1034. doi: 10.16766/j.cnki.issn.1674-4152.001973 LI L Y, XU P, WANG B D, et al. Research Progress of MicroRNA-429 in Gynecological Malignancies[J]. Chinese Journal of General Practice, 2021, 19(6): 1013-1016, 1034. doi: 10.16766/j.cnki.issn.1674-4152.001973
[18]	陈恩利, 楼俊晓, 王镇, 等. lncRNA GIHCG通过调节miR-429在原发性肝癌发生发展中的作用[J]. 中华全科医学, 2019, 17(5): 779-783. doi: 10.16766/j.cnki.issn.1674-4152.000790 CHEN E L, LOU J X, WANG Z, et al. lncRNA GIHCG plays a role in the occurrence and development of primary liver cancer by regulating miR-429[J]. Chinese Journal of General Practice, 2019, 17(5): 779-783. doi: 10.16766/j.cnki.issn.1674-4152.000790
[19]	PAN G, LIU Y, SHANG L, et al. EMT-associated microRNAs and their roles in cancer stemness and drug resistance[J]. Cancer Commun (Lond), 2021, 41(3): 199-217. doi: 10.1002/cac2.12138
[20]	YU L, CAO C, LI X, et al. Complete loss of miR-200 family induces EMT associated cellular senescence in gastric cancer[J]. Oncogene, 2022, 41(1): 26-36. doi: 10.1038/s41388-021-02067-y
[21]	FUNATO N, YANAGISAWA H. TBX1 targets the miR-200-ZEB2 axis to induce epithelial differentiation and inhibit stem cell properties[J]. Sci Rep, 2022, 12(1): 20188. DOI: 10.1038/s41598-022-24604-9.
[22]	GOLLAVILLI P N, PARMA B, SIDDIQUI A, et al. The role of miR-200b/c in balancing EMT and proliferation revealed by an activity reporter[J]. Oncogene, 2021, 40(12): 2309-2322. doi: 10.1038/s41388-021-01708-6
[23]	CHONG Z X, HO W Y, YEAP S K. Deciphering the roles of non-coding RNAs in liposarcoma development: challenges and opportunities for translational therapeutic advances[J]. Noncoding RNA Res, 2025, 11: 73-90. doi: 10.1016/j.ncrna.2024.11.005
[24]	NILSEN A, HILLESTAD T, SKINGEN V E, et al. miR-200a/b/-429 downregulation is a candidate biomarker of tumor radioresistance and independent of hypoxia in locally advanced cervical cancer[J]. Mol Oncol, 2022, 16(6): 1402-1419. doi: 10.1002/1878-0261.13184
[25]	CHOI P W, BAHRAMPOUR A, NG S K, et al. Characterization of miR-200 family members as blood biomarkers for human and laying hen ovarian cancer[J]. Sci Rep, 2020, 10(1): 20071. DOI: 10.1038/s41598-020-77068-0.
[26]	THI CHUNG DUONG T, NGUYEN T H N, THI NGOC NGUYEN T, et al. Diagnostic and prognostic value of miR-200 family in breast cancer: a meta-analysis and systematic review[J]. Cancer Epidemiol, 2022, 77: 102097. DOI: 10.1016/j.canep.2022.102097.
[27]	RAMIREZ-MOYA J, BAKER A R, SLACK F J, et al. ADAR1-mediated RNA editing is a novel oncogenic process in thyroid cancer and regulates miR-200 activity[J]. Oncogene, 2020, 39(18): 3738-3753. doi: 10.1038/s41388-020-1248-x
[28]	GHEIDARI F, AREFIAN E, SAADATPOUR F, et al. The miR-429 suppresses proliferation and migration in glioblastoma cells and induces cell-cycle arrest and apoptosis via modulating several target genes of ERBB signaling pathway[J]. Mol Biol Rep, 2022, 49(12): 11855-11866. doi: 10.1007/s11033-022-07903-2
[29]	NOVIKOV N M, ZOLOTARYOVA S Y, GAUTREAU A M, et al. Mutational drivers of cancer cell migration and invasion[J]. Br J Cancer, 2021, 124(1): 102-114. doi: 10.1038/s41416-020-01149-0
[30]	UHAN S, HAUPTMAN N. Metastatic EMT phenotype is governed by microrna-200-mediated competing endogenous RNA networks[J]. Cells, 2021, 11(1): 73. DOI: 10.3390/cells11010073.
[31]	ALAM F, MEZHAL F, EL HASASNA H, et al. The role of p53-microRNA 200-Moesin axis in invasion and drug resistance of breast cancer cells[J]. Tumour Biol, 2017, 39(9): 1010428317714634. DOI: 10.1177/1010428317714634.
[32]	LI D, WANG H, SONG H, et al. The microRNAs miR-200b-3p and miR-429-5p target the LIMK1/CFL1 pathway to inhibit growth and motility of breast cancer cells[J]. Oncotarget, 2017, 8(49): 85276-85289. doi: 10.18632/oncotarget.19205
[33]	CHEON I, LEE S, OH S, et al. miR-200-mediated inactivation of cancer-associated fibroblasts via targeting of NRP2-VEGFR signaling attenuates lung cancer invasion and metastasis[J]. Mol Ther Nucleic Acids, 2024, 35(2): 102194. DOI: 10.1016/j.omtn.2024.102194.
[34]	JING Y, LIANG W, LIU J, et al. Autophagy-mediating microRNAs in cancer chemoresistance[J]. Cell Biol Toxicol, 2020, 36(6): 517-536. doi: 10.1007/s10565-020-09553-1
[35]	YU S J, YANG L, HONG Q, et al. MicroRNA-200a confers chemoresistance by antagonizing TP53INP1 and YAP1 in human breast cancer[J]. BMC Cancer, 2018, 18(1): 1-11. doi: 10.1186/s12885-017-3892-2
[36]	PENG F, HE R, LIU Y, et al. MiR-200b-3p elevates 5-FU sensitivity in cholangiocarcinoma cells via autophagy inhibition by targeting KLF4[J]. Noncoding RNA Res, 2024, 9(4): 1098-1110. doi: 10.1016/j.ncrna.2024.06.004
[37]	FRISK N L S, SORENSEN A E, PEDERSEN O B V, et al. Circulating microRNAs for early diagnosis of ovarian cancer: a systematic review and meta-analysis[J]. Biomolecules, 2023, 13(5): 871. doi: 10.3390/biom13050871
[38]	FERNEZA S, FETSYCH M, SHULIAK R, et al. Clinical significance of microRNA-200 and let-7 families expression assessment in patients with ovarian cancer[J]. Ecancermedicalscience, 2021, 15: 1249. DOI: 10.3332/ecancer.2021.1249.
[39]	CITTELLY D M, DIMITROVA I, HOWE E N, et al. Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel[J]. Mol Cancer Ther, 2012, 11(12): 2556-2565. doi: 10.1158/1535-7163.MCT-12-0463
[40]	LIU J, ZHANG X, HUANG Y, et al. miR-200b and miR-200c co-contribute to the cisplatin sensitivity of ovarian cancer cells by targeting DNA methyltransferases[J]. Oncol Lett, 2019, 17(2): 1453-1460.
[41]	CHEN H, XIA B, LIU T, et al. KIAA0101, a target gene of miR-429, enhances migration and chemoresistance of epithelial ovarian cancer cells[J]. Cancer Cell Int, 2016, 16: 1-11.
[42]	SHAKER F, RAZI S, REZAEI N. Circulating miRNA and circulating tumor DNA application as liquid biopsy markers in gastric cancer[J]. Clin Biochem, 2024, 129: 110767. DOI: 10.1016/j.clinbiochem.2024.110767.
[43]	LIU L, LI P, WANG Q, et al. Diagnosis accuracy of the miR-200 family tumor marker series in ovarian cancer: a systematic review and meta-analysis[J]. Transl Cancer Res, 2022, 11(7): 2283-2290. doi: 10.21037/tcr-22-864
[44]	GUAN W, CUI H, HUANG P, et al. miR-200b/200a/429 cluster stimulates ovarian cancer development by targeting ING5[J]. J Oncol, 2020, 2020(1)3404059. DOI: 10.1155/2020/3404059.